Diphenhydramine and Doxylamine for Sleep: What OTC 'PM' Products Actually Do

Bottom line: Diphenhydramine and doxylamine can cause sedation, which is why they appear in so many OTC “PM” products. But the evidence for using first-generation antihistamines as a dependable long-term insomnia treatment is much weaker than their shelf presence suggests. Chronic-insomnia guidance specifically recommends against diphenhydramine, while doxylamine has some acute efficacy evidence but still carries the same basic anticholinergic and next-day-sedation concerns.[1-7]

Why antihistamines make you sleepy

Diphenhydramine and doxylamine are first-generation H1 antihistamines.

Unlike many newer allergy medications, they cross the blood-brain barrier readily. Blocking central histamine signaling produces drowsiness because histamine is one of the brain's wake-promoting neurotransmitter systems.

That mechanism is real.

But “this drug makes people sleepy” and “this drug is a good chronic insomnia treatment” are not the same claim.

A useful sleep treatment should be judged by outcomes such as:

• sleep-onset latency;
• wake after sleep onset;
• total sleep time;
• sleep efficiency;
• perceived sleep quality;
• daytime function;
• adverse effects; and
• whether benefit persists with repeated use.

What the AASM guideline says about diphenhydramine

The American Academy of Sleep Medicine reviewed randomized evidence for medications used in chronic insomnia.[1]

Its guideline suggests that clinicians not use diphenhydramine for either sleep-onset or sleep-maintenance insomnia in adults.

That recommendation is graded weak, which does not mean diphenhydramine is uniquely dangerous or never sedating. It means the available evidence did not support a favorable enough benefit-risk case for chronic insomnia.

This distinction matters because many consumers interpret OTC status as a kind of endorsement for nightly use. Regulatory availability and evidence-based insomnia treatment are different questions.

Doxylamine is not simply “the better antihistamine”

Doxylamine is another strongly sedating first-generation antihistamine and is widely sold for nighttime use.

A large 2022 network meta-analysis of insomnia medications found that doxylamine was more efficacious than placebo for acute treatment in the included evidence.[3]

That finding deserves to be preserved. It means the evidence is not accurately summarized as “antihistamines do nothing.”

But several limitations remain:

• the doxylamine evidence base is much smaller than for many prescription insomnia medications;
• acute efficacy does not establish long-term benefit;
• next-day sedation and anticholinergic effects still matter; and
• evidence for one drug cannot automatically validate every OTC combination product containing it.

A 2025 scoping review of randomized trials of OTC insomnia products reinforces how fragmented the evidence base remains.[2]

The evidence base is surprisingly thin for such common products

A 2016 systematic review specifically examined common OTC sleep agents including diphenhydramine and doxylamine.[4]

The striking point was not that no study ever found benefit. It was how little high-quality evidence existed relative to how commonly these products were used.

That imbalance is still relevant: a product can be familiar, inexpensive and available in every pharmacy without having a modern evidence base comparable to first-line insomnia therapy.

Sedation can hide poor sleep quality

People often judge a sleep aid by one immediate question:

Did it knock me out faster?

That can miss several important outcomes.

A person may fall asleep more quickly but wake groggy, have impaired alertness, or feel cognitively dulled the next morning. A strong subjective sedative effect can therefore coexist with a poor overall tradeoff.

A double-blind PET crossover study provides unusually direct evidence for that concern: after a nighttime 50 mg diphenhydramine dose, substantial brain H1-receptor occupancy was still measurable the following morning.[7] That does not mean every user will feel equally impaired, but it confirms that central antihistamine activity can persist well beyond bedtime.

This is one reason the sleep cluster separates sleep onset from next-day function instead of treating “felt sleepy” as the entire endpoint.

Tolerance changes the long-term question

Sedating antihistamines are often used repeatedly because the first few nights feel effective.

Tolerance is not just theoretical. In a randomized double-blind crossover study, healthy adults received diphenhydramine 50 mg twice daily for four days. Objective and subjective sleepiness were clearly higher than placebo initially, but by day four the sedative effect was no longer distinguishable from placebo; psychomotor impairment showed the same rapid adaptation pattern.[6]

That study evaluated daytime sedation rather than bedtime insomnia treatment, so it should not be converted into an exact rule that “Benadryl stops working after three nights.” It does, however, show that central tolerance to diphenhydramine sedation can develop remarkably quickly.

This creates a basic problem for chronic use: the effect that made the product attractive may not remain stable.

Escalating use in response to reduced sedation increases exposure to anticholinergic and next-day effects without proving that sleep quality is improving.

Anticholinergic effects are the safety story people miss

First-generation antihistamines do more than block histamine. They also have anticholinergic activity.

Common adverse effects can include:

• dry mouth;
• constipation;
• blurred vision;
• urinary retention;
• dizziness;
• confusion; and
• next-day drowsiness.

These risks are especially important in older adults.

The 2023 American Geriatrics Society Beers Criteria identify first-generation antihistamines as medications that are generally best avoided in older adults in many circumstances because of their anticholinergic burden.[5]

This does not mean every younger adult taking a single dose faces the same risk profile. It means the consumer framing of these drugs as benign “nighttime allergy pills” can hide clinically meaningful pharmacology.

Older adults are a different risk category

Age changes the decision substantially.

Older adults are more vulnerable to anticholinergic adverse effects, including confusion, falls, urinary retention and cognitive effects. The Beers Criteria exist precisely because medications that appear routine in younger adults can become disproportionately risky with age.[5]

So an article about diphenhydramine for sleep should never give a universal verdict without separating older adults from younger populations.

Combination “PM” products create another trap

Many OTC nighttime products pair an antihistamine with another drug such as acetaminophen or ibuprofen.

That means a person who wants sedation may unintentionally take a pain reliever they do not need.

The evidence question should therefore be ingredient-specific, not brand-specific:

• What is the sedating ingredient?
• Is another active drug included?
• Is that second ingredient actually needed?
• Are there overlapping medications being taken elsewhere?

A familiar brand name can make this duplication easy to miss.

What about occasional use?

The evidence is more favorable to the narrow concept of occasional, short-term sedation than to nightly chronic-insomnia treatment.

That does not make short-term use automatically appropriate for every person. Driving, alcohol, other sedatives, urinary problems, glaucoma risk, pregnancy, age and other medications can change the safety calculation.

But it does explain why someone may truthfully report that an OTC antihistamine helped them sleep while professional chronic-insomnia guidance remains unfavorable.

Those statements are not contradictory. They are answering different questions.

Chronic insomnia deserves a different framework

If sleep difficulty persists for weeks or months, repeatedly adding sedation can obscure the underlying problem.

Chronic insomnia may involve conditioned arousal, circadian timing, sleep apnea, restless legs, medication effects, mood disorders, pain, substance use or inadequate sleep opportunity.

Cognitive behavioral therapy for insomnia remains the evidence benchmark for chronic insomnia, while sedating antihistamines occupy a much narrower role.

Bottom line

Diphenhydramine and doxylamine are pharmacologically active sedatives, not fake sleep aids. But their real sedative effect is often mistaken for a stronger evidence claim than the literature supports.

For diphenhydramine, AASM guidance suggests against use for chronic sleep-onset or sleep-maintenance insomnia.[1] Doxylamine has some acute randomized evidence, but its evidence base is comparatively thin and long-term benefit is not established.[2-4]

The biggest practical limits are rapid tolerance, next-day impairment, anticholinergic effects and older-adult risk.[5-7]

The most defensible verdict is: possible short-term sedation, weak support as a chronic insomnia strategy, and a safety profile that deserves much more respect than the OTC label implies.

Related reading

• CBT-I vs Sleep Supplements
• Sleep Onset vs Sleep Maintenance
• Insomnia vs Sleep Deprivation
• Alcohol and Sleep